Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention

Clinical Infectious Diseases

Volumn 61, Issue 8, 2015, Pages 1322-1327

  Podany, Anthony T ^a   Bao, Yajing ^b   Swindells, Susan ^c   Chaisson, Richard E ^d   Andersen, Janet W ^b   Mwelase, Thando ^e   Supparatpinyo, Khuanchai ^f   Mohapi, Lerato ^e   Gupta, Amita ^d   Benson, Constance A ^g   Kim, Peter ^h   Fletcher, Courtney V ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f Faculty of Medicine Chiang Mai University   (Thailand)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

HIV AIDS; Pharmacodynamics; Pharmacokinetics; Rifapentine; Tuberculosis

Indexed keywords

EFAVIRENZ; ISONIAZID; PYRIDOXINE; RIFAPENTINE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; ORAL CLEARANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; ISOLATION AND PURIFICATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ISONIAZID; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; RNA, VIRAL; TUBERCULOSIS;

EID: 84943232683     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ464     Document Type: Article

References (33)

1. World Health Organization. Global tuberculosis report 2013.
2. Horsburgh CR, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010; 137:401-9.
3. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155-66.
4. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365:11-20.
5. Centers for Disease Control Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60:1650.
6. TB CARE I. International standards for tuberculosis care, 3rd ed. The Hague: TB CARE I, 2014.
7. Sanofi-Aventis: Priftin (rifapentine) [package insert] August 2007. Available at: http://products.sanofi.us/priftin/priftin.pdf. Accessed 15 January 2015.
8. Keung A, Reith K, Eller M, McKenzie K, Cheng L, Weir S. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I. Int J Tuberc Lung Dis 1999; 3:426-36.
9. US Department of Health Human Services. Panel on antiretroviral therapy and medical management of HIV infected children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2012. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/Pediatric Guidelines.pdf. Accessed 15 January 2013.
10. US Department of Health Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 12 February 2013. 2013. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 12 February 2013.
11. World Health Organization. Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/. Accessed 1 August 2013.
12. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
13. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV?1?positive adults with antiretroviral therapy 2012 (updated November 2013). HIV Med 2014; 15(suppl 1): 1-6.
14. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-5.
15. Chen TT. Optimal three?stage designs for phase II cancer clinical trials. Stat Med 1997; 16:2701-11.
16. Fletcher C, Brundage R, Fenton T, et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther 2007; 83:300-6.
17. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource, 2009.
18. Fattinger K, Fellay J, Telenti A, Biollaz J, Buclin T. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73:20-30.
19. Schechter M, Zajdenverg R, Falco G, et al.Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006; 173:922-6
20. Di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19:300-9.
21. Wen X,Wang J-S, Neuvonen PJ, Backman JT. Isoniazid is a mechanismbased inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002; 57:799-804.
22. Almutairi FE, Greenblatt DJ, Hazarika S, et al. Isoniazid mediates the CYP2B6 6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6. Antimicrob Agents Chemother 2014; 58:4145-52.
23. HaasDW, Kwara A, Richardson DM, et al. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIVinfected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother 2014; 69:2175-82.
24. Lee L, Soon G, Chew N, Else L, Amara A, Knoo S. Differential induction of efavirenzmetabolismby rifampin without and with isoniazid in healthy volunteers with CYP2B6 516GG and TT genotypes [abstract 516]. In: 20th Conference on Retroviruses and Opportunistic Infections, 2013:3-6.
25. Luetkemeyer AF, Rosenkranz SL, Lu D, et al. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis 2015; 60:1860-3.
26. McIlleron HM, Schomaker M, Ren Y, et al. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS 2013; 27:1933.
27. Sanofi-Aventis: Rifadin (rifampin) [package insert] June 2014.
28. Liu J, Chan-Tack K, Jadhav P, et al. Why did the FDA approve efavirenz 800 mg when co-administered with rifampin? Int J Clin Pharmacol Ther 2014; 52:446-53.
29. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58:1299-302.
30. ManosuthiW, Kiertiburanakul S, Sungkanuparph S, et al. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20:131-2.
31. Luetkemeyer AF, Rosenkranz SL, Lu D, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis 2013; 57:586-93.
32. Dooley KE, Denti P, Martinson N, et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis co-infection. J Infect Dis 2015; 211:197-205.
33. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 1:CD000171.